I can share a quick update on CFTR news, but I don’t have live browsing access here. If you’d like, I can summarize recent themes and point you to reliable sources to check now.
-
What CFTR refers to: CFTR is the gene encoding the cystic fibrosis transmembrane conductance regulator protein, whose dysfunction causes cystic fibrosis (CF) and also has roles studied in cancer and other diseases. Recent public discussion often centers on modulators that improve CFTR protein function or expression, and on novel approaches like gene editing or molecular prosthetics. For context, approved CFTR modulators have substantially changed CF management in many patients, though access and mutation-specific efficacy remain important issues [general CFTR context].
-
Recent themes you’ll see in current news:
- Advances in CFTR modulators and combination therapies, including next-generation correctors and potentiators, and their clinical trial outcomes.
- Research into extending benefits to broader CF mutations and improving quality of life and lung function.
- Investigations into CFTR biology that could inform new therapies, including alternative strategies like gene editing or prosthetic approaches for cases with minimal CFTR protein.
-
How to verify latest news quickly:
- Check dedicated CF organizations’ news pages (e.g., Cystic Fibrosis Foundation, Cystic Fibrosis Trust) for press releases and trial updates.
- Look for recent NEJM, Lancet Respiratory, or major medical center press releases on new modulators or gene-editing progress.
- Search for terms like “CFTR modulators latest trial results,” “VX-659 VX-445 triple combination update,” or “CFTR gene editing progress 2026” on reputable medical news sites.
If you want, tell me your preferred focus (clinical trial updates, new therapies, or basic science breakthroughs) and I’ll tailor a concise, up-to-date briefing and provide citations to current sources.
Sources
CLEVELAND - Results of the pivotal Phase 3 clinical trial published in the Nov. 3, 2011 New England Journal of Medicine, find that the oral medicatio...
case.edua collaboration with the CF Foundation (CFF). This CF research program would work to find medications, called modulators, to correct defective CFTR protein. Since the start of this collaboration, Vertex has developed Kalydeko® (ivacaftor), Orkambi® (lumacaftor/ivacaftor) and … paved the way for other CFTR modulators that may benefit many more patients. In 2015, lumacaftor/ivacaftor (Orkambi) combination therapy was approved by the FDA for patients with two F508del mutations (the most common CF...
www.med.umich.eduThere's been advancement on cystic fibrosis, but there are still those living with the disease who get no relief from current treatments. Gene editing may help.
www.nhlbi.nih.govA new study confirms ivacaftor's impact on inflammation in people with cystic fibrosis (CF). Ivacaftor targets the defective protein that causes CF.
news.cuanschutz.eduA Potential Breakthrough Treatment for Cystic Fibrosis Enters Clinical Trial Led by CI MED and U of Iowa Researchers
medicine.illinois.eduLARVOL VERI predictive biomarker news, CFTR (CF Transmembrane Conductance Regulator)
veri.larvol.comProfessor Tzyh-Chang Hwang Deciphers Pathogenic Protein Structure, Advancing Drug Development for Cystic Fibrosis and Diarrheal Diseases
www.nycu.edu.twCystic fibrosis lung cells were restored to 50 percent of healthy function in work that provides the first evidence that novel therapeutic strategies for human patients can be identified based on yeast studies.
www.uab.eduHow are a football match, a plug socket and a birthday cake linked to CFTR, the gene that causes cystic fibrosis? Find out by reading our ‘Research blast’ article celebrating 30 years since the gene was discovered.
www.cysticfibrosis.org.uk